Abstract
Melanoma and non-melanoma skin cancers (NMSCs) are two major forms of skin cancers. Melanoma is the most aggressive form of skin cancer related deaths while basal cell carcinoma (BCC) and squamous cell carcinoma (SCC) are most prevalent forms of NMSCs with over 5.3million yearly cases in the US. Due to huddles including resistance, bioavailability and adverse effects with available treatments, there is the need for effective strategies against skin cancer progression. The cyclin dependent kinase-2(CDK2), c-kit and mammalian target of rapamycin (mTOR), are attractive targets for new anticancer drug development.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
